氨基酸混合液脱色条件的比较选择

以四种粉末状活性炭作为脱色剂,对猪血粉水解液进行脱色比较,结果表明：江西产的４号粉末状活性炭脱色效果最佳。本文还对４号脱色炭的脱色条件进行了摸索研究。     

L-鸟氨酸发酵液的脱色研究

为了提高L-鸟氨酸发酵液的脱色效率,对其脱色工艺开展研究。首先通过树脂的选择性吸附确定L-鸟氨酸发酵液中色素的化学性质,随后结合颗粒活性炭的物理结构和零电荷点分析,优选出在接近中性条件下具有优良脱色性能的颗粒活性炭。在静态条件下考察pH、温度、时间和活性炭用量等因素对其脱色性能的影响。在此基础上,考察活性炭层析柱对L-鸟氨酸发酵液的动态脱色工艺和基于两步解吸法的活性炭再生工艺,单柱可动态脱色处理45倍床层体积(BV)的发酵液,脱色率达97%以上,脱色液呈无色透明状,L-鸟氨酸损失率低于1%,活性炭再生效果保持稳定。     

板蓝根多糖活性炭脱色工艺及抗氧化活性研究北大核心CSCD

采用活性炭对板蓝根多糖进行了脱色研究。在单因素实验的基础上进行了正交实验,得到活性炭脱色的最佳工艺条件为:70℃下调节p H为7.0,添加体积分数为1.0%的活性炭,搅拌80 min,脱色率为92.97%、多糖保留率为92.45%。采用DPPH孤电子配对法测定DPPH自由基的清除作用;采用邻苯三酚自氧化法检测超氧阴离子自由基的清除作用。实验结果表明,板蓝根多糖具有一定的清除自由基的能力,但脱色后的多糖清除自由基的能力降低。     

板蓝根多糖活性炭脱色工艺及抗氧化活性研究

采用活性炭对板蓝根多糖进行了脱色研究。在单因素实验的基础上进行了正交实验,得到活性炭脱色的最佳工艺条件为:70℃下调节p H为7.0,添加体积分数为1.0%的活性炭,搅拌80 min,脱色率为92.97%、多糖保留率为92.45%。采用DPPH孤电子配对法测定DPPH自由基的清除作用;采用邻苯三酚自氧化法检测超氧阴离子自由基的清除作用。实验结果表明,板蓝根多糖具有一定的清除自由基的能力,但脱色后的多糖清除自由基的能力降低。     

木本植物蛋白提取和SDS-PACE分析方法的比较和优化

在几种木本植物上对4种常用蛋白提取方法、4种凝胶染色和脱色方法及影响蛋白定量和SDS-PAGE电泳的因素进行了比较研究,发现：利用改良丙酮沉降法提取蛋白,不仅提取效率高,而且杂质干扰少,得到的电泳结果,蛋白条带清晰,数量多;将常规凝胶染色和脱色液中的乙醇改用为甲醇可大大改善染色和脱色效果,获得了没有背景或背景很浅的电泳结果。通过研究确定了一套优化的适用于木本植物的蛋白提取、定量、凝胶制备、电泳、染色、脱色以及干胶制备的方法。利用这一优化方法对胡杨细胞盐胁迫蛋白进行了研究,发现了与高水平盐胁迫有关的66kD蛋白和与盐胁迫和干旱胁迫均有关的28kD蛋白,获得了满意的蛋白SDS-PAGE分析结果。     

陕北红枣中多糖的酶加水法提取工艺研究

以多糖含量和得率为指标,采用正交试验法对陕北红枣中多糖的提取与分离工艺进行优选。酶加水提取的最佳工艺为：①温度70℃、酶添加量3．0％、时间2h;②温度70℃、酶添加量2．0％、时间4h。分离的最佳工艺为：分级沉淀多糖时采用浓缩液：无水乙醇（v／v）1：3效果最好;当采用活性炭脱色时,活性炭用量为7g／L时,既达到了脱色的目的,多糖的损失率又较小。     

菜籽降压肽双酶水解液脱色工艺的研究

用活性炭对菜籽降压肽双酶水解液进行脱色处理,采用单因素试验以及单因素试验基础上的正交试验法。考察活性炭用量、pH、温度、时间对水解液脱色率、肽损失率、活性及ACE抑制率的影响。正交试验优化结果表明,菜籽降压肽双酶水解液脱色最佳工艺为活性炭的用量为1%、脱色pH值为3.0、脱色温度为80℃、脱色时间为50 min,在此条件下脱色率为85.52%、ACE抑制率为57.83%、活性损失率为5.69%。     

活性炭脱色的工艺设计

<正> 在医药、制糖、、化肥、氨基酸等工业生产中,许多产品都要经过活性炭脱色以去除色素。例如,用毛发酸水解提取胱氨酸的生产工艺中要经过两次脱色,才能使胱氨酸产品的澄明度合格。为了更好地指导生产,尽可能地节约生产原料,减少有效物质的损失,本文就活性炭脱色的工艺设计进行了理论上探讨。     

木本植物蛋白提取和SDS-PAGE分析方法的比较和优化

在几种木本植物上对４种常用蛋白提取方法、４种凝胶染色和脱色方法及影响蛋白定量和ＳＤＳＰＡＧＥ电泳的因素进行了比较研究,发现：利用改良丙酮沉降法提取蛋白,不仅提取效率高,而且杂质干扰少,得到的电泳结果,蛋白条带清晰,数量多;将常规凝胶染色和脱色液中的乙醇改用为甲醇可大大改善染色和脱色效果,获得了没有背景或背景很浅的电泳结果。通过研究确定了一套优化的适用于木本植物的蛋白提取、定量、凝胶制备、电泳、染色、脱色以及干胶制备的方法。利用这一优化方法对胡杨细胞盐胁迫蛋白进行了研究,发现了与高水平盐胁迫有关的６６ｋＤ蛋白和与盐胁迫和干旱胁迫均有关的２８ｋＤ蛋白,获得了满意的蛋白ＳＤＳＰＡＧＥ分析结果。     

猴头菌多糖不同脱色方法的研究

为选择最适于猴头菌多糖的脱色方法,本论文先比较了活性炭吸附法、化学脱色法、大孔树脂法等三种常用的脱色方法对猴头菌多糖的脱色效果及脱色前后免疫活性的变化,发现大孔树脂法更适合于猴头菌多糖的脱色,接着对十种不同类型的大孔树脂进行了筛选,通过脱色前后脱色率、多糖保留率及体外免疫活性的比较,最后发现大孔弱碱性阴离子树脂D315最适合用于猴头菌粗多糖的脱色.     

The effect of ferrous sulfate and pH on L-dopa absorption

Ferrous sulfate decreases L-dopa bioavailability in humans probably as a result of binding of L-dopa by iron in the gastrointestinal tract. This study was conducted to determine if iron by binding L-dopa decreases L-dopa absorption and to investigate the effect of different pH buffers on intestinal absorption of L-dopa in the presence and absence of ferrous sulfate. A rat model developed to examine drug absorption was used. Control animals had buffered [14C]L-dopa solutions injected into two in vivo closed segments of intestine; a 5-cm duodenal and a 5-cm proximal jejunal segment. These studies were conducted using solutions buffered at pH 5.5, 6.5, 7.5, and 8.5. An identical procedure was followed for experimental animals except ferrous sulfate was injected with the buffered L-dopa solutions. Ferrous sulfate resulted in a reduction in L-dopa absorption in the buffers at all pHs in both the duodenum and jejunum. The average reduction in L-dopa absorption in the presence of iron was 22.6% in the duodenum and 23.9% in the jejunum. There was a tendency for ferrous sulfate to cause a greater reduction in L-dopa absorption as the buffer pH increased. There was also a decrease in L-dopa absorption in the higher pH buffers in the absence of iron. Despite this latter result, in the jejunum there was an increase in the percent reduction in L-dopa absorption associated with ferrous sulfate as pH increased. Although this tendency was not as consistent in the duodenum as the jejunum, the combined results are compatible with the chemical model of increased L-dopa--iron binding as pH increases.     

Independent Component Analysis of the Effect of L-dopa on fMRI of Language Processing

L-dopa, which is a precursor for dopamine, acts to amplify strong signals, and dampen weak signals as suggested by previous studies. The effect of L-dopa has been demonstrated in language studies, suggesting restriction of the semantic network. In this study, we aimed to examine the effect of L-dopa on language processing with fMRI using Independent Component Analysis (ICA). Two types of language tasks (phonological and semantic categorization tasks) were tested under two drug conditions (placebo and L-dopa) in 16 healthy subjects. Probabilistic ICA (PICA), part of FSL, was implemented to generate Independent Components (IC) for each subject for the four conditions and the ICs were classified into task-relevant source groups by a correlation threshold criterion. Our key findings include: (i) The highly task-relevant brain regions including the Left Inferior Frontal Gyrus (LIFG), Left Fusiform Gyrus (LFUS), Left Parietal lobe (LPAR) and Superior Temporal Gyrus (STG) were activated with both L-dopa and placebo for both tasks, and (ii) as compared to placebo, L-dopa was associated with increased activity in posterior regions, including the superior temporal area (BA 22), and decreased activity in the thalamus (pulvinar) and inferior frontal gyrus (BA 11/47) for both tasks. These results raise the possibility that L-dopa may exert an indirect effect on posterior regions mediated by the thalamus (pulvinar).     

Evidence for L-dopa incorporation into cell proteins in patients treated with levodopa

Levodopa (L-dopa) is the most widely used agent for the symptomatic relief of Parkinson's disease. There is concern that chronic L-dopa treatment may be detrimental, with some studies suggesting that L-dopa may be neurotoxic. A potentially important mechanism whereby L-dopa may exert neurotoxic effects has been overlooked: that of the incorporation of L-dopa into proteins by protein synthesis. L-Dopa competes with tyrosine as a substrate in protein synthesis in vitro. We provide evidence that L-dopa can also be incorporated into proteins in vivo. Blood from L-dopa-treated and -non-treated patients was separated into protein, erythrocyte and lymphocyte fractions and levels of protein-incorporated dopa quantified by HPLC. Levels of protein-incorporated dopa were significantly increased in lymphocyte cell proteins from L-dopa-treated patients. This has not arisen from oxidative pathways as there was no evidence of oxidative damage to proteins. In addition, there was no increase in protein-incorporated dopa in erythrocytes, which are not actively synthesizing proteins. We suggest that protein-incorporated dopa could also be generated in the CNS. The accumulation of protein-incorporated dopa in cells is associated with oxidative stress and impaired function and could contribute to some of the problems associated with long-term L-dopa treatment.     

Histochemical observations on uptake of L-dopa into endocrine cells of the rat pituitary gland during the postnatal development

The uptake of L-dopa into the cells of the adenohypophysis of the rat was studied during the postnatal development and at adult age using the formaldehyde-induced fluorescence method (FIF). The cells taking up L-dopa were classified by Alcian blue-PAS-Orange G staining. The correlation between the cells taking up L-dopa and those containing tryptophyl-peptide was estimated during the postnatal period and in adult rats. The cells containing tryptophyl-peptide were demonstrated using fluorescence induced by treatment with combined formaldehyde and acetyl chloride vapour. The following observations were made: 1) Great majority of the cells taking up L-dopa did not contain tryptophyl-peptide. Thus the accumulation of L-dopa into the cells of pars distalis is not due to accumulation of L-dopa into the cells by the same transport mechanism as the amino acids for tryptophyl-peptide. 2) Of the cells taking up L-dopa in the adult rats 96% were chromophobes, 2.0% acidophilic cells (somatotrophs and cells producing prolactin), 0.9% R-mucoid cells (corticotrophs), and 1.2% S1- and S2-mucoid cells (gonadotrophs and thyrotrophs). At 10 and 25 days' age the relative numbers of the cells taking up L-dopa were about the same. 3) Pretreatment with nialamide caused only a slight increase in the number of the cells taking up L-dopa. The decrease in the number of the cells uptaking L-dopa of the pars distalis, which takes place after 5 weeks' age is thus not caused by the increased MAO-activity. 4) Strongly chromophilic cells did not take up L-dopa. At the light of our results it seems evident that L-dopa is taken up by the chromophobic cells when these differentiate into chromophilic cells. The accumulation of L-dopa may be a sign of an active transport of amino acids into the cells. The accumulation of L-dopa into the chromophobic stellate and follicular cells may reflect their metabolic activity. These cells probably have an important role in the production of the hormones of the pars distalis.     

Effects of L-dopa treatment on methylation in mouse brain: implications for the side effects of L-dopa

The effects of L-dopa on methylation process in the mouse brain were investigated. The study is based on recent findings that methylation may play an important role in Parkinson's disease (PD) and in the actions of L-dopa. The methyl donor, S-adenosylmethionine (SAM) and a product of SAM, methyl beta-carboline, were shown to cause PD-like symptoms, when injected into the brain of animals. Furthermore, large amounts of 3-O-methyl dopa, the methyl product of L-dopa, are produced in PD patients receiving L-dopa treatment, and L-dopa induces methionine adenosyl transferase, the enzyme that produces SAM. The results show that, at 0.5 hr, L-dopa (100 mg/kg) decreased the methyl donor, S-adenosylmethionine (SAM) by 36%, increased its metabolite S-adenosylhomocysteine (SAH) by 89% and increased methylation (SAH/SAM) by about 200%. All parameters returned to control values within 4 hr. But 2, 3 and 4 consecutive injections of L-dopa, given at 45 min intervals, depleted SAM by 60, 64 and 76% and increased SAM/SAH to 818, 896, and 1524%. L-dopa (50, 100 and 200 mg/kg) dose-dependently depleted SAM from 24.9 +/- 1.7 nmol/g to 13.0 +/- 0.8, 14.7 +/- 0.8 and 7.7 +/- 0.7 nmol/g, and increased SAH from 1.88 +/- 0.14 to 3.43 +/- 0.26, 4.22 +/- 0.32 and 6.21 +/- 0.40 nmol/g. Brain L-dopa was increased to 326, 335 and 779%, dopamine to 138, 116 and 217% and SAH/SAM to 354, 392 and 1101%. The data show that L-dopa depletes SAM, and increases methylation 4-5 times more than dopamine, therefore, methylation may play a role in the actions of L-dopa. This and other studies suggest that the high level of utilization of methyl group by L-dopa leads to the induction of enzymes to replenish SAM and to increase the methylation of L-dopa as well as DA. These changes may be involved in the side effects of L-dopa.     

O-Methylation of L-dopa in Melanin Metabolism and the Presence of Catechol-O-Methyltransferase in Melanocytes

O-Methylation of L-dopa was investigated as a possible regulatory mechanism in melanin metabolism. The methylation product of L-dopa, 3-O-methoxytvrosine was detected in extracts of cultured human melanocytes. The enzyme catechol-O-methyltransferase is responsible for this O-methylation and that of the dihydroxyindolic intermediates of melanogenesis. The enzyme is present in melanocytes in its soluble and membrane-bound isoforms. Immuno-electron microscopy suggests the presence of the membrane-bound enzyme in the endoplasmic reticulum. This localization may indicate a role of catechol-O-methyltransferase in protecting the melanocyte against reactive dihydroxyphenolic intermediates of melanogenesis leaking from the melanogenic compartments. On the other hand, the O-methylation of L-dopa may serve as a regulatory point in melanogenesis during early stage of tyrosinase processing in the endoplasmic reticulum.     

Mediated exodus of L-dopa from human epidermal Langerhans cells

Summary. L-3,4-dihydroxyphenylalanine (L-dopa) is not metabolized within human epidermal Langerhans cells (LC); yet they can take up substantial amounts of this amino acid which subsequently can be released into the extracellular space. We recently reported that human epidermal energy metabolism is predominantly anaerobic and that the influx mechanism is a unidirectional L-dopa/proton counter-transport system and now we describe conditions for the mediated transport of L-dopa out of the LC. It is demonstrated that certain amino acids and one dipeptide can effectively trigger the efflux of L-dopa taken up by the LC.Thus, -methyl-dopa (-m-dopa), D-dopa and the dipeptide, met–ala at the outside of the plasma membrane stimulated the efflux of L-dopa from L-dopa loaded LC. Similar effects were achieved by a variety of other amino acids in the extracellular fluid while some other amino acids were inactive. The time required for 50% D-methionine-induced exodus of L-dopa from L-dopa loaded LC was in the range of 5–7min and a complete exodus of L-dopa was attained at about 20min of incubation. This dislocation of L-dopa to the extracellular fluid is interpreted as an expression of trans-stimulation. In the case of -m-dopa, D-dopa and met–ala, which admittedly were not able to penetrate the plasma membrane of LC, the concept of trans-stimulation was given a new purport, since none of them were able to participate in an exchange reaction. Finally, it could be concluded that L-dopa escaped by a route different from the one responsible for L-dopa uptake in LC.Thus, while the influx of L-dopa supports extrusion of protons deriving from anaerobic glycolysis in the LC, L-dopa efflux can provide the cells with useful amino acids in an energy-saving way, altogether a remarkable biological process. From this follows that L-dopa has a biological function of its own, besides being a precursor in the catecholamine and pigment syntheses.     

Controlled clinical trial of L-dopa and nafoxidine in advanced breast cancer: an E.O.R.T.C. study.

L-Dopa lowers plasma prolactin levels, and there have been reports that patients with advanced breast cancer have been successfully treated with L-dopa. To test the potential value of L-dopa in this disease a randomized clinical trial of L-dopa and nafoxidine (as the reference compound) was conducted in postmenopausal women with advanced breast cancer. Objective remissions were obtained in sever out of 36 patients (19%) treated with nafoxidine but in none out of 40 patients treated with L-dopa. L-Dopa in the dose schedule used seems to be ineffective in advanced breast cancer.     

Determination of L-dopa using electropolymerized 3,3',3',3'-tetraaminophthalocyanatonickel(II) film on glassy carbon electrode

Electropolymerized film of 3,3',3',3'-tetraaminophthalocyanatonickel(II) (p-Ni(II)TAPc) on glassy carbon (GC) electrode was used for the selective and stable determination of 3,4-dihydroxy-L-phenylalanine (L-dopa) in acetate buffer (pH 4.0) solution. Bare GC electrode fails to determine the concentration of L-dopa accurately in acetate buffer solution due to the cyclization reaction of dopaquinone to cyclodopa in solution. On the other hand, p-Ni(II)TAPc electrode successfully determines the concentration of L-dopa accurately because the cyclization reaction was prevented at this electrode. It was found that the electrochemical reaction of L-dopa at the modified electrode is faster than that at the bare GC electrode. This was confirmed from the higher heterogeneous electron transfer rate constant (k(0)) of L-dopa at p-Ni(II)TAPc electrode (3.35 x 10(-2) cms(-1)) when compared to that at the bare GC electrode (5.18 x 10(-3) cms(-1)). Further, it was found that p-Ni(II)TAPc electrode separates the signals of ascorbic acid (AA) and L-dopa in a mixture with a peak separation of 220 mV. Lowest detection limit of 100 nM was achieved at the modified electrode using amperometric method. Common physiological interferents like uric acid, glucose and urea does not show any interference within the potential window of L-dopa oxidation. The present electrode system was also successfully applied to estimate the concentration of L-dopa in the commercially available tablets.     

Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure

L-3,4-dihydroxypheylalanine (L-dopa)-induced dyskinesia represent a debilitating complication of therapy for Parkinson's disease (PD) that result from a progressive sensitization through repeated L-dopa exposures. The MPTP macaque model was used to study the proteome in dopamine-depleted striatum with and without subsequent acute and chronic L-dopa treatment using two-dimensional difference in-gel electrophoresis (2D-DIGE) and mass spectrometry. The present data suggest that the dopamine-depleted striatum is so sensitive to de novo L-dopa treatment that the first ever administration alone would be able (i) to induce rapid post-translational modification-based proteomic changes that are specific to this first exposure and (ii), possibly, lead to irreversible protein level changes that would be not further modified by chronic L-dopa treatment. The apparent equivalence between first and chronic L-dopa administration suggests that priming would be the direct consequence of dopamine loss, the first L-dopa administrations only exacerbating the sensitization process but not inducing it.